PUBLIC COMPANY
save$TLSATiziana Life Sciences Ltd
$TLSALondon, England, GBupdated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
- phase2The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab
- phase2A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
- —Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
- phase2Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
- phase1Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
🐶 Hiring Signal
News
- UniQure gets review date and adcomm; Inovio's stock surges after approvalPlus news about AbbVie, Gilead and Tiziana Life Sciences. FDA gives uniQure a review date and adcomm: The agency will decide whether or not to approve uniQure’s high-profile Huntington’s disease ge…endpoints · 18d ago
- Tiziana touts multiple sclerosis win at lower dose as high dose misses markIn a mid-stage trial, the lower dose of Tiziana’s intranasal monoclonal antibody reduced microglial activation in a specific type of multiple sclerosis. But the path forward remains unclear after t…biospace · 18d ago
- Lower dose of Tiziana's MS drug reduces neuroinflammation, while higher dose strugglesTiziana Life Sciences’ intranasal drug has hit the dual endpoints of a phase 2a study in patients with a form of multiple sclerosis (MS), although the win was slightly marred by the higher dose mis…fiercebiotech · 18d ago
- From strategy to scale: How Saudi Arabia is building a biotech ecosystemSaudi Arabia’s biotech strategy now has named partners, sites and capital behind it.biopharma_dive · 1mo ago
- Tiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerBOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with i…globenewswire_health · 3mo ago
- Tiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerBOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with i…globenewswire_health · 3mo ago
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that